A Phase 3 interventional study of Ustekinumab and Guselkumab in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 87 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-09-12.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing ustekinumab in Psoriasis — 4 open to participants now, 4 under way, none of them phase 3. Ustekinumab · Psoriasis.
Among the 31 studies testing ustekinumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 16 in phase 3, and was the 20th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 31 studies testing ustekinumab in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Ustekinumab: first FDA approval 2009 (STELARA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 872 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 158 across the 31 interventional studies. Of the 25 that completed or were terminated, 20 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 6th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2014, is one of 36 in phase 3, and was the 37th registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing ustekinumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270733University Hospitals Cleveland Medical CenterDevelopment of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing ustekinumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.
This is a randomized (assignment of study drug by chance), double-blind (participants nor study staff will know the identity of study drugs), multicenter study to evaluate efficacy and safety of guselkumab for the treatment of participants with moderate to severe plaque-type psoriasis who had an inadequate response to ustekinumab. The study will consist of a screening period, open-label and double-blind treatment periods, and a follow-up period. The treatment period will have 2 phases: an open-label treatment phase during which all participants will receive ustekinumab at Weeks 0 and 4 and a blinded treatment phase during which participants with an inadequate Investigator's Global Assessment response (IGA≥2) to ustekinumab at Week 16 will be randomized to receive either guselkumab or ustekinumab through Week 44. Participants with an IGA response of 0 or 1 (cleared or minimal disease) at Week 16 will continue to receive open-label treatment with ustekinumab every 12 weeks through Week 40. All participants will complete a follow-up phase through Week 52 for efficacy and through Week 60 for safety evaluations. The total duration of the study will be approximately 64 weeks (includes a 4-week screening period). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ustekinumab
Drug: Guselkumab · Drug: Placebo for ustekinumab
Drug: Ustekinumab · Drug: Placebo for guselkumab
45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 28 through Week 40
Number of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 40
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
Time frame: Week 28 through Week 40
Number of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 40
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 28 through Week 40
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 28
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 28
| Milestone | Ustekinumab (Open Label Run-in) | 100 mg Guselkumab (Randomized) | Ustekinumab (Randomized) | Ustekinumab (Nonrandomized Open Label Continuation) |
|---|---|---|---|---|
| Started | 872 | 0 | 0 | 0 |
| Treated | 871 | 0 | 0 | 0 |
| Completed | 853 | 0 | 0 | 0 |
| Not completed | 19 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 1 | 0 | 0 | 0 |
| Milestone | Ustekinumab (Open Label Run-in) | 100 mg Guselkumab (Randomized) | Ustekinumab (Randomized) | Ustekinumab (Nonrandomized Open Label Continuation) |
|---|---|---|---|---|
| Started | 0 | 135 | 133 | 585 |
| Completed | 0 | 120 | 107 | 539 |
| Not completed | 0 | 15 | 26 | 46 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 | 8 |
| Withdrew: Withdrawal by subject | 0 | 8 | 19 | 20 |
| Withdrew: Other | 0 | 4 | 1 | 15 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Completed safety follow-up | 0 | 1 | 3 | 2 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| visits | Guselkumab (Randomized) | Ustekinumab (Randomized) |
|---|---|---|
| Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40 | 1.5 ± 1.57 | 0.7 ± 1.26 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
| visits | Guselkumab (Randomized) | Ustekinumab (Randomized) |
|---|---|---|
| Number of Visits at Which Participants Achieved a Psoriasis Area and Severity Index (PASI) 90 Response From Week 28 Through Week 40 | 2.2 ± 1.69 | 1.1 ± 1.53 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| visits | Guselkumab (Randomized) | Ustekinumab (Randomized) |
|---|---|---|
| Number of Visits at Which Participants Achieved an IGA Score of Cleared (0) From Week 28 Through Week 40 | 0.9 ± 1.34 | 0.4 ± 1.06 |
The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Guselkumab (Randomized) | Ustekinumab (Randomized) |
|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) at Week 28 | 31.1 | 14.3 |
Collected over Up to Week 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ustekinumab (Open Label Run-in) | — | 11/871 (1.3%) | 80/871 (9.2%) |
| 100 mg Guselkumab (Randomized) | — | 9/135 (6.7%) | 37/135 (27.4%) |
| Ustekinumab (Randomized) | — | 6/133 (4.5%) | 33/133 (24.8%) |
| Ustekinumab (Nonrandomized Open Label Continuation) | — | 20/585 (3.4%) | 60/585 (10.3%) |
| Event | Ustekinumab (Open Label Run-in) | 100 mg Guselkumab (Randomized) | Ustekinumab (Randomized) | Ustekinumab (Nonrandomized Open Label Continuation) |
|---|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 0/871 | 2/135 | 0/133 | 0/585 |
| Acute Myocardial InfarctionCardiac disorders | 0/871 | 0/135 | 1/133 | 1/585 |
| Back PainMusculoskeletal and connective tissue disorders | 0/871 | 0/135 | 1/133 | 0/585 |
| EczemaSkin and subcutaneous tissue disorders | 0/871 | 0/135 | 1/133 | 0/585 |
| Diabetes MellitusMetabolism and nutrition disorders | 0/871 | 0/135 | 1/133 | 0/585 |
| Type 2 Diabetes MellitusMetabolism and nutrition disorders | 0/871 | 0/135 | 1/133 | 0/585 |
| Retinal DetachmentEye disorders | 0/871 | 0/135 | 1/133 | 0/585 |
| Angina UnstableCardiac disorders | 0/871 | 1/135 | 0/133 | 0/585 |
| Toxicity to Various AgentsInjury, poisoning and procedural complications | 0/871 | 1/135 | 0/133 | 0/585 |
| Transitional Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/871 | 1/135 | 0/133 | 0/585 |
| Event | Ustekinumab (Open Label Run-in) | 100 mg Guselkumab (Randomized) | Ustekinumab (Randomized) | Ustekinumab (Nonrandomized Open Label Continuation) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 47/871 | 23/135 | 23/133 | 33/585 |
| Upper Respiratory Tract InfectionInfections and infestations | 33/871 | 15/135 | 11/133 | 27/585 |
Baseline analysis included all participants who were enrolled at Week 0 and received at least 1 dose of study agent administration.
| Age, Categorical(Participants) | Ustekinumab (Open Label Run-in) |
|---|---|
| <=18 years | 4 |
| Between 18 and 65 years | 814 |
| >=65 years | 53 |
| Age, Continuous(years) | Ustekinumab (Open Label Run-in) |
|---|---|
| Mean | 43.1 ± 13.21 |
| Sex: Female, Male(Participants) | Ustekinumab (Open Label Run-in) |
|---|---|
| Female | 305 |
| Male | 566 |
| Region of Enrollment(participants) | Ustekinumab (Open Label Run-in) |
|---|---|
| Germany | 96 |
| Poland | 294 |
| Russia | 88 |
| Spain | 24 |
| United Kingdom | 11 |
| Canada | 61 |
| United States | 194 |
| Australia | 19 |
| Korea, Republic Of | 29 |
| Taiwan, Province Of China | 55 |
Ran from Oct 2014 to primary completion in Dec 2015, 14 months.
Results were first posted in Jul 2017, 1 year 6 months after primary completion. A results delay was requested in Jul 2016.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ustekinumab · Guselkumab
Janssen Research & Development, LLC →